
浏览全部资源
扫码关注微信
400016 重庆,重庆医科大学生命科学研究院
[徐晨,E-mail: xuchen@cqmu.edu.cn XU Chen, E-mail: xuchen@cqmu.edu.cn
收稿:2021-05-06,
修回:2021-07-16,
纸质出版:2021-09-30
移动端阅览
陈津滢, 张咪, 曾燕, 等. 副交感神经M1受体通过Caspase-1/GSDMD通路调控前列腺癌细胞焦亡[J]. 第三军医大学学报, 2021,43(18):1796-1805.
Jinying CHEN, Mi ZHANG, Yan ZENG, et al. Muscarinic acetylcholine M1 receptor regulates pyroptosis of prostate cancer cells through Caspase-1/GSDMD pathway[J]. Journal of Third Military Medical University, 2021, 43(18): 1796-1805.
陈津滢, 张咪, 曾燕, 等. 副交感神经M1受体通过Caspase-1/GSDMD通路调控前列腺癌细胞焦亡[J]. 第三军医大学学报, 2021,43(18):1796-1805. DOI: 10.16016/j.1000-5404.202105010.
Jinying CHEN, Mi ZHANG, Yan ZENG, et al. Muscarinic acetylcholine M1 receptor regulates pyroptosis of prostate cancer cells through Caspase-1/GSDMD pathway[J]. Journal of Third Military Medical University, 2021, 43(18): 1796-1805. DOI: 10.16016/j.1000-5404.202105010.
目的
2
探讨副交感神经M1受体(muscarinic acetylcholine M1 receptor,CHRM1)对前列腺癌细胞焦亡的影响及其可能的分子机制。
方法
2
在PC-3细胞中分别于12、24、48 h加入不同浓度CHRM1特异性抑制剂哌仑西平(pirenzepine,PIN)和激动剂氯贝胆碱(bethanechol,BECH),后用慢病毒感染PC-3细胞构建CHRM1敲低的稳转株,再用质粒转染构建成孔蛋白gasdermin D(GSDMD)的敲低细胞模型,CCK-8实验检测细胞增殖能力,乳酸脱氢酶(lactate dehydrogenase,LDH)细胞毒性检测试剂检测LDH释放水平,流式细胞术及荧光倒置显微镜下观察Hoechst-PI和Annexin V-PI双染后的PI阳性细胞率,通过透射电镜观察细胞焦亡现象,Western blot检测Caspase-1/GSDMD通路相关分子的表达水平。
结果
2
CHRM1特异性抑制剂哌仑西平及慢病毒敲低CHRM1可使前列腺癌细胞PC-3细胞活力下降(
P
<
0.05),PI阳性细胞数显著增加(
P
<
0.01),同时在透射电镜下可观察到明显细胞焦亡现象,而相对的加入激动剂氯贝胆碱可使其细胞活力在一定浓度范围内上升(
P
<
0.05),PI阳性细胞率减少(
P
<
0.01);通过药物和慢病毒下调CHRM1之后,Caspase-1/GSDMD通路中的天冬氨酸蛋白水解酶-1 (Caspase-1)、天冬氨酸蛋白水解酶剪切体-1(cleaved Caspase-1)、凋亡相关斑点样蛋白(ASC)、炎症复合体(NLRP3)及GSDMD水平明显上升(
P
<
0.05);敲低GSDMD之后,PI阳性细胞率降低(
P
<
0.05),LDH释放率降低(
P
<
0.001),各相关蛋白水平显著下降(
P
<
0.01),且抑制或敲低CHRM1后PI阳性细胞率、LDH释放率及各相关蛋白水平无明显回复。
结论
2
下调CHRM1可通过Caspase-1/GSDMD通路诱导前列腺癌细胞焦亡。
Objective
2
To determine the effect of muscarinic acetylcholine M1 receptor (CHRM1) on pyroptosis of prostate cancer cells and investigate its possible molecular mechanism.
Methods
2
Pirenzepine (PIN)
a specific CHRM1 antagonist
and bethanechol (BETH)
its agonist
were used to treat PC-3 cells at different doses for different time periods (12
24 and 48 h). Then a stable PC-3 cell strain cells with CHRM1 knockdown was established by lentivirus infection. A knockdown cell model of gasdermin D (GSDMD) was constructed by plasmid transfection. Cell proliferation ability was detected by CCK8 assay
LDH release level was measured by lactate dehydrogenase (LDH) cytotoxicity assay
and the rate of PI positive cells after staining with Hoechst-PI and Annexin V-PI was observed by flow cytometry and fluorescence inversion microscopy. Cell pyroptosis was observed by transmission electron microscopy and protein expression levels related to pyroptosis pathway were detected by Western blotting.
Results
2
The specific inhibitor of CHRM1
pirenzepine
and lentivirus knockdown of CHRM1 reduc
ed the cell viability of PC-3 cells (
P
<
0.05)
and increased the rate of PI positive cells significantly (
P
<
0.01). At the same time
the phenomenon of cell pyroptosis was observed under electron microscope
and the treatment of the BETH enhanced the cell viability (
P
<
0.05) and reduced the rate of PI positive cells in a certain concentration range (
P
<
0.01). After the down-regulation of CHRM1 by drugs and lentiviruses
the proteins levels of Caspase-1/GSDMD pathway
Caspase-1
cleaved Caspase-1
apoptosis associated speck-like protein (ASC)
NOD-
LRR- and pyrin domain-containing protein 3 (NLRP3) and GSDMD were significantly increased (
P
<
0.05). After the GSDMD was knocked down
the rate of PI positive cells was decreased (
P
<
0.05)
LDH release was reduced (
P
<
0.001)
and the levels of related proteins were reduced significantly (
P
<
0.01). Treatment of CHRM1 inhibitor or knockdown of CHRM1 had no effects on the rate of PI positive cells
LDH release
and the levels of related proteins.
Conclusion
2
Down-regulation of CHRM1 induces pyroptosis of prostate cancer cells through Caspase-1/GSDMD pathway.
BRAY F, FERLAY J, SOERJOMATARAM I, et al . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J ] . CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
YANG Y Y, LIU K Y, LIU Q, et al . Androgen receptor-related non-coding RNAs in prostate cancer[J ] . Front Cell Dev Biol, 2021, 9: 660853. DOI: 10.3389/fcell.2021.660853.
MAGNON C, HALL S J, LIN J, et al . Autonomic nerve development contributes to prostate cancer progression[J ] . Science, 2013, 341(6142): 1236361. DOI: 10.1126/science.1236361.
PENNEFATHER J N, LAU W A, MITCHELSON F, et al . The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies[J ] . J Auton Pharmacol, 2000, 20(4): 193-206. DOI: 10.1046/j.1365-2680.2000.00195.x.
张咪, 王千慧, 陈津滢, 等. 交感神经β2肾上腺素受体促进前列腺癌转移并抵抗肿瘤细胞的凋亡[J]. 第三军医大学学报, 2019, 41(21): 2051-2060. DOI: 10.16016/j.1000-5404.201906119.
ZHANG M, WANG Q H, CHEN J Y, et al . Sympathetic β2 adrenergic receptor promotes prostate cancer metastasis and resists tumor cell apoptosis[J ] . J Third Mil Med Univ, 2019, 41(21): 2051-2060. DOI: 10.16016/j.1000-5404.201906119.
BAIG A M, IQBAL J, KHAN N A. In vitro efficacies of clinically available drugs against growth and viability of an Acanthamoeba castellanii keratitis isolate belonging to the T4 genotype[J ] . Antimicrob Agents Chemother, 2013, 57(8): 3561-3567. DOI: 10.1128/AAC.00299-13.
ESPAÑOL A J, DE LA TORRE E, FISZMAN G L, et al . Role of non-neuronal cholinergic system in breast cancer progression[J ] . Life Sci, 2007, 80(24/25): 2281-2285. DOI: 10.1016/j.lfs.2006.12.017.
KAMIYA A, HIYAMA T, FUJIMURA A, et al . Sympathetic and parasympathetic innervation in cancer: therapeutic implications[J ] . Clin Auton Res, 2021, 31(2): 165-178. DOI: 10.1007/s10286-020-00724-y.
KAMIYA A, HAYAMA Y, KATO S, et al . Genetic manipulation of autonomic nerve fiber innervation and activity and its effect on breast cancer progression[J ] . Nat Neurosci, 2019, 22(8): 1289-1305. DOI: 10.1038/s41593-019-0430-3.
COLE S W, NAGARAJA A S, LUTGENDORF S K, et al . Sympathetic nervous system regulation of the tumour microenvironment[J ] . Nat Rev Cancer, 2015, 15(9): 563-572. DOI: 10.1038/nrc3978.
BERTHELOOT D, LATZ E, FRANKLIN B S. Necroptosis, pyroptosis and apoptosis: an intricate game of cell death[J]. Cell Mol Immunol, 2021, 18(5): 1106-1121. DOI: 10.1038/s41423-020-00630-3.
KRUSE A C, KOBILKA B K, GAUTAM D, et al . Muscarinic acetylcholine receptors: novel opportunities for drug development[J ] . Nat Rev Drug Discov, 2014, 13(7): 549-560. DOI: 10.1038/nrd4295.
WITTE L P, TEITSMA C A, DE LA ROSETTE J J, et al . Muscarinic receptor subtype mRNA expression in the human prostate: association with age, pathological diagnosis, prostate size, or potentially interfering medications?[J ] . Naunyn Schmiedebergs Arch Pharmacol, 2014, 387(2): 207-214. DOI: 10.1007/s00210-013-0934-4.
DEGTEREV A, YUAN J Y. Expansion and evolution of cell death programmes[J]. Nat Rev Mol Cell Biol, 2008, 9(5): 378-390. DOI: 10.1038/nrm2393.
BEDOUI S, HEROLD M J, STRASSER A. Emerging connectivity of programmed cell death pathways and its physiological implications[J]. Nat Rev Mol Cell Biol, 2020, 21(11): 678-695. DOI: 10.1038/s41580-020-0270-8.
YU P, ZHANG X, LIU N, et al . Pyroptosis: mechanisms and diseases[J ] . Signal Transduct Target Ther, 2021, 6(1): 128. DOI: 10.1038/s41392-021-00507-5.
XIA X, WANG X, CHENG Z, et al . The role of pyroptosis in cancer: pro-cancer or pro- "host"?[J ] . Cell Death Dis, 2019, 10(9): 650. DOI: 10.1038/s41419-019-1883-8.
BERGSTRÖM S H, JÄREMO H, NILSSON M, et al . Prostate tumors downregulate microseminoprotein-beta (MSMB) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness[J ] . Prostate, 2018, 78(4): 257-265. DOI:10.1002/pros.23466.
KARAN D, TAWFIK O, DUBEY S. Expression analysis of inflammasome sensors and implication of NLRP12 inflammasome in prostate cancer[J]. Sci Rep, 2017, 7(1): 4378. DOI: 10.1038/s41598-017-04286-4.
FISCHER F A, CHEN K W, BEZBRADICA J S. Posttranslational andtherapeutic control of gasdermin-mediated pyroptosis and inflammation[J]. Front Immunol, 2021, 12: 661162. DOI: 10.3389/fimmu.2021.661162.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621